[Use of pyridoxal phosphate and L-dopa in the treatment of cardiac insufficiency in patients with mitral defects and the active phase of rheumatism].
The effects of pyridoxal phosphate (PALP) and L-DOPA on the central hemodynamics and myocardial contractility were studied in 61 patients with associated heart insufficiency and active rheumatic fever. Introduction of PALP into a complex of treatment measures in a dose of 0.06 g a day for 21--24 days provides a more demonstrable effect than that of L-DOPA in a dose of 1.5 g a day for the same time. It is advisable to include PALP into a complex treatment of heart insufficiency in patients with associated mitral valve and active rheumatic fever.
D000328:Adult; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008946:Mitral Valve Stenosis / Q000150:complications*; D009200:Myocardial Contraction / Q000187:drug effects; D011732:Pyridoxal Phosphate / Q000494:pharmacology / Q000627:therapeutic use*; D012213:Rheumatic Fever / Q000150:complications*
D007980:Levodopa; D011732:Pyridoxal Phosphate
Primenenie piridoksalfosfata i L-dofa pri lechenii serdechnoĭ nedostatochnosti u bol'nykh mitral'nym porokom s aktivnoĭ fazoĭ revmatizma.